Neuroinflammatory Imaging Using TSPO PET Tracer in Paients With Autoimmune Encephalomyelitis
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Autoimmune Encephalomyelitis
- Sponsor
- Ruijin Hospital
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- TSPO expression level
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
Autoimmune encephalomyelitis is a heterogeneous group of central nervous system (CNS) autoimmune diseases characterized by the production of anti-neuron-associated autoantibodies which target neuronal surface proteins, synaptic receptors and intracellular antigens. MRI, as a current first-line imaging tool of CNS inflammation, is difficult to diagnose them because the majority of patients have normal MRI images, and only a few may show local signal or structural abnormalities (including inflammation, edema, or atrophy). The 18 kDa translocator protein (TSPO) expression in the CNS is upregulated in response to microglia activation. DPA-714 is high affinity for binding to TSPO, making 18F-labeled DPA-714 (18F-DPA-714) PET a very promising diagnostic imaging tool for neuroinflammation in patients with autoimmune encephalomyelitis.This study aims to explore the value of 18F-DPA-714 PET in the early diagnosis, therapeutic assessment and prognosis in patients with autoimmune encephalomyelitis.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
TSPO expression level
Time Frame: 12 months after baseline
quantitatively assessing the level of neuroinflammation in all brain regions or spinal cord